Showing results (851-860 of 988) with videos related to
Sort By:
Pageof 99
European Journal of Human Genetics : EJHG|April 30, 2015
Common polygenic variation in coeliac disease and confirmation of ZNF335 and NIFA as disease susceptibility lociCiara Coleman, Emma M Quinn, Anthony W Ryan, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2013
Phase I trial of preoperative chemoradiation plus sorafenib for high-risk extremity soft tissue sarcomas with dynamic contrast-enhanced MRI correlatesJanelle M Meyer, Kelly S Perlewitz, James B Hayden, et al.Journal of Gynecologic Oncology|April 17, 2026
A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: vaginal cancer sub cohort resultsYoung Kwang Chae, Josie Czeskleba, Sandip Pravin Patel, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2008
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033Charles D Blanke, Cathryn Rankin, George D Demetri, et al.JAMA Oncology|February 15, 2017
Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033Michael C Heinrich, Cathryn Rankin, Charles D Blanke, et al.Frontiers in Oncology|August 26, 2024
Frequency of pathogenic germline variants in pediatric medulloblastoma survivorsDonald Rees, D Matthew Gianferante, Jung Kim, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 26, 2024
Randomized, Double-Blind Phase III Study of Pazopanib Versus Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasectomy: ECOG-ACRIN E2810Leonard J Appleman, Se Eun Kim, Wayne B Harris, et al.Cancer|November 12, 2024
A phase 4, multicenter, global clinical study to evaluate discontinuation and rechallenge of pexidartinib in patients with tenosynovial giant cell tumor previously treated with pexidartinibJayesh Desai, Andrew J Wagner, Irene Carrasco Garcia, et al.Cancer|February 8, 2017
The American Cancer Society's Cancer Prevention Study 3 (CPS-3): Recruitment, study design, and baseline characteristicsAlpa V Patel, Eric J Jacobs, Daniela M Dudas, et al.The Lancet. Oncology|January 23, 2016
Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trialAndrew J Armstrong, Susan Halabi, Tim Eisen, et al.Pageof 99